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Abstract
In 1998 a collaboration between Duke University and the University of North Carolina, Chapel Hill (UNC) was
founded to enhance identification of persons with acute HIV-1 infection (AHI). The Duke-UNC AHI Research
Consortium Cohort consists of patients ‡ 18 years old with a positive nucleic acid amplification test (NAAT) and
either a negative enzyme immunoassay (EIA) test or a positive EIA with a negative/indeterminate Western blot.
Patients were referred to the cohort from acute care settings and state-funded HIV testing sites that use NAAT
testing on pooled HIV-1 antibody-negative samples. Between 1998 and 2010, 155 patients with AHI were
enrolled: 81 (52%) African-Americans, 63 (41%) white, non-Hispanics, 137 (88%) males, 108 (70%) men who have
sex with men (MSM), and 18 (12%) females. The median age was 27 years (IQR 22–38). Most (n = 138/155)
reported symptoms with a median duration of 17.5 days. The median nadir CD4 count was 408 cells/mm3 (IQR
289–563); the median observed peak HIV-1 level was 726,859 copies/ml (IQR 167,585–3,565,728). The emergency
department was the most frequent site of initial presentation (n = 55/152; 3 missing data). AHI diagnosis was
made at time of first contact in 62/137 (45%; 18 missing data) patients. This prospectively enrolled cohort is the
largest group of patients with AHI reported from the Southeastern United States. The demographics reflect the
epidemic of this geographic area with a high proportion of African-Americans, including young black MSM.
Highlighting the challenges of diagnosing AHI, less than half of the patients were diagnosed at the first
healthcare visit. Women made up a small proportion despite increasing numbers in our clinics.
Introduction
Acute HIV-1 infection (AHI) can be defined as the pe-riod between HIV-1 acquisition and the development of
HIV-1-specific antibodies. Although screening tests have
markedly improved in terms of earlier detection and diag-
nostic accuracy, HIV-1 antibodies are usually not detected
during the earliest phase of infection when patients often have
the highest levels of viremia. Since routine HIV-1 antibody
tests are typically negative during the first few weeks of in-
fection, the diagnosis of AHI during this period requires a
high index of suspicion and use of specific tests for viral nu-
cleic acid or HIV-1 antigens. Unfortunately, symptoms of AHI
are common, nonspecific,1,2 and often mistaken for other ill-
nesses. The failure to identify AHI is especially significant as
acutely infected patients are often highly infectious due to
high levels of viremia.3,4 After diagnosis, HIV-1-infected pa-
tients have been observed to reduce high-risk behaviors, thus
diminishing risk of transmission.5–7 Initiation of antiretroviral
therapy (ART) also reduces transmission by decreasing viral
replication and shedding in infectious fluids.8–11 Thus, timely
diagnosis of AHI has become an important public health
measure.12,13
To enhance identification and management of persons with
AHI, the Duke-UNC Acute HIV Infection Research Con-
sortium was founded as a collaboration between Duke Uni-
versity and the University of North Carolina, Chapel Hill
(UNC). Patients identified during AHI, either clinically or by
pooled screening strategies, have been enrolled since 1998.
We describe our cohort of AHI patients diagnosed in South-
eastern United States. To better understand and characterize
this population, we analyzed the cohort by a variety of factors
including site of initial presentation and HIV-1 antibody sta-
tus at time of diagnosis—enzyme immunoassay (EIA) sero-
negative or EIA seropositive with a negative or indeterminate
Western blot (WB).
1Duke University, Durham, North Carolina.
2University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
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The Duke-UNC AHI Cohort consists of patients ‡ 18 years
old diagnosed with AHI between January 1, 1998 and De-
cember 31, 2010. Enrolled patients had a positive nucleic acid
amplification test (NAAT) and either a negative EIA test or a
positive EIA with a negative or indeterminate WB. An inde-
terminate WB was defined as detection of fewer than two of
the following bands: gp120/160, gp41, or p24.
Patients with AHI were referred to the cohort from acute
care settings [emergency departments (ED), urgent care cen-
ters, student health centers, or primary care clinics] and from
the North Carolina State Screening and Tracing for Active
HIV-1 Transmission (STAT) program. In 2002 the North
Carolina Department of Health and Human Services and the
North Carolina State Laboratory of Public Health initiated the
STAT program to diagnose AHI using NAAT testing of
pooled HIV-1 antibody-negative samples.14,15 This program
tests all persons presenting to publicly funded testing sites in
NC for AHI (if the initial HIV-1 antibody test is negative or
indeterminate).15 Specimens with detectable HIV-1 RNA that
are either EIA negative or EIA positive with a negative/in-
determinate WB are considered acute infections and are
confirmed by subsequent HIV-1 antibody testing
Patients enrolled in the cohort had demographic informa-
tion recorded including age, gender, race/ethnicity, and self-
reported sexual orientation. At the time of study enrollment
(typically within 2 weeks of diagnosis), patients were asked
by a research study team member about symptoms consistent
with AHI, including start and stop dates. The site and date of
initial presentation and the number of visits to healthcare
settings for similar symptoms prior to diagnosis were also
collected. CD4 counts and HIV-1 levels were measured and
recorded at time points as close as possible to the date of AHI
diagnosis (defined as the collection date of the first positive
HIV-1 RNA test); there were no specific criteria set for the
duration of chart review for either the CD4 nadir or peak
HIV-1 level. Follow-up EIA results were used to estimate the
date of seroconversion; the estimated date of infection was
defined as occurring 14 days prior to onset of symptoms.1,16,17
For 10/17 patients without symptoms, BEAST (Bayesian
Evolutionary Analysis by Sampling Trees v.1.5.3) analysis
performed in an earlier study on this cohort was used to es-
timate the date of infection.17 The protocol was approved by
the Institutional Review Boards at each institution; written
informed consent was obtained from all study participants.
Descriptive statistics, including frequencies for categorical
variables and medians with interquartile ranges (IQR) for
continuous variables are presented in this analysis. Ad-
ditionally, we assessed trends in yearly enrollment by race,
age, and sexual risk group. Finally, we examined differences
by site of initial presentation and compared patients who
initially presented to a health department or related publicly
funded facility vs. those presenting to an acute care setting
(ED, urgent care center, student health center, or primary care
clinic). An AHI diagnosis was not always made at the site of
first presentation. Comparisons were also made between pa-
tients who were EIA negative vs. EIA positive with a nega-
tive/indeterminate WB at the time of diagnosis, both of which
served as criteria for enrollment.
Quantitative variables were described using means and
standard deviations (SD) in cases where the underlying dis-
tribution was normal; medians with ranges were used for
variables without normal distributions. Differences in con-
tinuous variables between the groups were analyzed using
the Student’s t test (mean) or Wilcoxon rank-sum testing
(median). To compare categorical variables, we used Pear-
son’s v2 with Fisher’s exact test to account for small num-
bers. Statistical significance was defined as a < 0.05 for all
analyses. All statistical analyses were performed using SAS
v.9.2 (Cary, NC).
Results
Between January 1, 1998 and December 31, 2010, 155 pa-
tients with AHI were enrolled; of these 137 (88%) were male
(Table 1). Annual enrollment increased in 2003 with the in-
ception of the STAT program. The median age at diagnosis
was 27 years (IQR 22–38), with a range of 17–66 years (Fig. 1).
Most patients were African-American (n = 81; 52%) or white,
non-Hispanic (n = 63; 41%). Men who have sex with men
(MSM) were the most common risk group (n = 108; 70%),
followed by heterosexual men (n = 24; 15%) and women
(n = 18; 12%). No patients endorsed injection drug use.
Acutely infected males were younger than females with a
median age of 26 (IQR 22–36) vs. 33 years (IQR 22–43). No-
tably, the number of patients who were black MSM £ 30 years
old increased over time (Fig. 2). From 1998 to 2001, 10.5% of
newly diagnosed patients were young, black MSM, which
increased to 26.7% from 2002–2006 and 44.8% from 2007–2010
( p = 0.02).
Most patients reported symptoms at presentation sugges-
tive of acute retroviral syndrome (138/155; 89%). The median
duration of symptoms was 17.5 days (IQR 7–33). The three
most frequently reported symptoms were fever (66%), fatigue
(57%), and body ache (54%) (Table 2). Females were more apt
to complain of fatigue (56%), followed by fever (50%), body
ache (50%), and nausea (50%). Although more women than
men reported symptoms [17/18 women (94%) vs. 121/137
(88.3%)], the median duration of symptoms was shorter
among women than men (9 vs. 18 days), and women reported
fewer symptoms overall (median number of symptoms: 4.5
vs. 6).
For the overall cohort the median initial CD4 count was 484
cells/mm3 (IQR 340–675) and the median nadir CD4 count
was 408 cells/mm3 (IQR 289–563). However, 39% (n = 60) had
a nadir £ 350 cells/mm3, 14% (n = 21) had a nadir < 200 cells/
mm3, and 5% (n = 7) had a nadir < 50 cells/mm3 (Fig. 3a). The
median time from diagnosis to nadir CD4 count collection
was 25 days (IQR 14–181).
The median initial HIV-1 level was 569,399 copies/ml (IQR
91,980–2,260,000) and the median observed peak HIV-1 level
was 726,859 copies/ml (IQR 167,585–3,565,728). Thirty-two
percent (n = 50) had an initial HIV-1 level ‡ 1,000,000 copies/ml
at diagnosis, while 9% (n = 14) had an initial HIV-1 level
< 10,000 copies/ml (Fig. 3b). In 10 patients (8 of whom were
EIA negative at diagnosis), serial HIV-1 levels prior to sero-
conversion did not exceed 10,000 copies/ml; in 29 patients (23
were EIA negative at diagnosis) preseroconversion HIV-1
levels did not exceed 100,000 copies/ml. Conversely, 17 (11%)
patients had peak HIV-1 levels ‡ 10,000,000 copies/ml with
the highest HIV-1 level observed at 160,000,000 copies/ml.
Patients with initial HIV-1 levels < 100,000 copies/ml had
higher median CD4 count nadirs compared to those with initial












































































































































































































































































































































































































































































































































































































































































































































































































































































HIV-1 levels > 100,000 copies/ml (502 vs. 375 cells/mm3;
p = 0.0009), in addition to fewer symptoms (median number of
symptoms 4.5 vs. 6; p = 0.02). Women had lower initial HIV-1
levels than men (median 64,263 vs. 596,000 copies/ml) and
higher initial CD4 counts (median 629 vs. 457 cells/mm3).
Fifty-two (33.3%) patients had an increase in HIV-1 level from
the first measurement to the second, suggesting early diagnosis
during the viral expansion phase and prior to peak HIV-1
levels.
Comparison by site of initial presentation
The ED was the most frequent site of first clinical presen-
tation (n = 55/152; 36%; three missing data) followed by the
health department (n = 46/152; 30%) and primary care clinic
(n = 27/152; 18%) (Table 3). Patients initially presenting to a
health department tended to be younger than those present-
ing to acute care settings (median age 24 vs. 29 years; p = 0.09)
(Table 1). There was also a trend toward African-Americans
presenting first to a health department rather than acute care
setting (70% vs. 45%; p = 0.09). There were no significant dif-
ferences in gender or sexual risk groups when comparing sites
of presentation. Patients presenting to acute care sites were
more often symptomatic than those presenting to a health
department (93% vs. 83%; p = 0.04) and reported more
symptoms (median number of symptoms 6 vs. 5; p = 0.08).
Patients presenting to a health department had significantly
higher median nadir and initial CD4 counts and lower median
initial and peak viral loads compared to those presenting to
acute care settings (Table 1).
FIG. 2. Frequency of men who
have sex with men (MSM) £ 30
years of total AHI cohort (N = 155)
by race and calendar year.
FIG. 1. Age distribution at diag-
nosis of acute HIV-1 infection (AHI)
patients in North Carolina.
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Comparison by initial EIA
One hundred and three patients (67%) had an initial neg-
ative EIA test; 50/153 (33%; two missing data) presented with
a positive EIA with a negative/indeterminate Western blot.
There were no significant differences in age, race/ethnicity, or
gender/sexual risk category between these two groups (Table
1). Symptomatic AHI was more common in persons with
negative EIA results compared to patients with positive EIA
results (94% vs. 84%; p = 0.1), but the median number of
symptoms was identical (n = 6). Median nadir CD4 counts and
initial CD4 counts were slightly lower among the EIA-nega-
tive group. Both median initial viral loads and peak viral
loads were higher in the EIA-negative group (Table 1).
Timeline
Overall, less than half of the cohort (n = 62/137; 45%;
18 missing data) was diagnosed with AHI at their first
healthcare visit. Seventy-five patients (55%) required one or
more healthcare encounters before AHI diagnosis was
made, and 29 patients (21%) were diagnosed after two or more
visits. Among 46 patients with initial presentation to a health
department, the majority (n = 36/37; 97%; 9 missing data)
were diagnosed at first visit. Conversely, of the 100 patients
presenting initially to acute care settings with data on the
number of healthcare visits before diagnosis, 26 (26%) were
diagnosed at first visit, and 74 (74%) experienced one or more
healthcare visits prior to their AHI diagnosis (6 missing data).
Overall, the median time from initial presentation to di-
agnosis was 2 days, but ranged from 0 to 90 days (IQR 0–8
days), with a mean time of 6 days. The median time from
estimated date of infection to presentation was 18 days (IQR
15–25 days), but ranged from 4 to 68 days. The median time
from estimated date of infection to diagnosis was 23 days
(IQR 18–31).
The median time from initial presentation to diagnosis was
significantly shorter for patients who presented to a health
department vs. acute care setting (0 vs. 4 days; p < 0.001). The
median time from estimated date of infection to presentation
was significantly longer for patients presenting to a health
department vs. acute care setting (23 vs. 17 days; p = 0.001).
The median time from estimated date of infection to diagnosis
did not differ by site of presentation.
FIG. 3. (a) Initial and nadir CD4 counts in acutely infected
patients. (b) Initial and peak HIV-1 levels in acutely infected
patients.
Table 2. Symptoms of Acute HIV Infection
All N (%)
N 155
Any symptom 138 (89)
Median number of symptoms (IQR) 6 (4–8)
Fever 103 (66)
Fatigue 88 (57)




Loss of appetite 69 (45)
Sore throat 57 (37)
Night sweats 56 (36)
Weight loss 54 (35)
Swollen lymph nodes 51 (33)
Rash 41 (26)
Stomach pain 34 (22)
Joint pain 24 (15)
Cough 26 (17)
Thrush 22 (14)
Sores/ulcers mouth 14 (9)
Table 3. Sites of Initial Presentation to Care and HIV
Diagnosis Among Acute HIV Infection Patients
Site of initial presentation to carea (N = 152) N %
Health Department 46 30
Acute Care settings
Emergency Department 55 52
Primary Care Clinic 27 25
Urgent Care Center 14 13




Site of HIV diagnosisc (N = 127) N %
Health Department 65 51
Acute Care settings
Emergency Department 13 21
Primary Care Clinic 42 68
Urgent Care Center 0 0




aThree patients missing data on initial site of presentation.
bOther includes prenatal clinic, prison blood draw, and commu-
nity outreach.
cTwenty-eight patients missing site of HIV diagnosis (defined as
date of collection of first positive HIV-1 RNA test).
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The median time from initial presentation to diagnosis was
shorter for EIA negative vs. EIA positive patients (1 vs. 5 days;
p = 0.06), as was the median time from estimated date of in-
fection to diagnosis (21 vs. 26 days; p = 0.01). Notably, the
median time from estimated date of infection to presentation
for these two groups was quite similar (17 vs. 19 days; p = 0.2).
Discussion
For the past 13 years, the Duke-UNC AHI Research Con-
sortium has enrolled AHI patients, including those recog-
nized during clinical illness characteristic of AHI and those
identified from a state-wide screening program for antibody-
negative specimens collected from publically funded testing
centers. This prospectively enrolled cohort is the largest
population of AHI reported to date from the Southeastern
United States. Demographic characteristics of the population
are broad and generally reflect the epidemic of this geo-
graphic area with a high proportion of African-Americans. In
our cohort, racial preponderance among AHI cases has
evolved; approximately half (50%) were white in 2003, with
an increase in African-Americans from 56% in 2007 to 67% of
the total cohort in 2010. These characteristics distinguish the
present cohort from other AHI studies, where African-
Americans are often underrepresented (constituting only
7–18% of the population1,18,19), despite the fact that this racial
group accounts for 44% of all new HIV-1 infections.20 Recent
incidence data indicate that young black MSM have become
the driver of new HIV-1 infections nationwide.21 This trend is
reflected in our cohort wherein black MSM £ age 30 represent
34% and comprise a significantly increasing percentage over
recent years. The composition of our cohort may reflect the
demographics of HIV-1 in the Southeast United States and/or
the pooled screening procedure that ultimately established
the diagnosis in 53% of our patients (n = 82). This population-
based approach likely accesses a more representative group of
persons at risk for AHI than do more focused diagnostic
strategies.
As in other published AHI cohorts,1,22 the majority of our
patients (89%) were symptomatic. Of concern, only 45% were
diagnosed at their first healthcare encounter, highlighting the
challenges of diagnosing AHI, including insufficient assess-
ment of patient risk factors, failure of healthcare providers to
consider AHI as a potential diagnosis, limited knowledge
regarding proper diagnostic testing, and lack of easy access to
diagnostic tools. The general absence of a defined infrastruc-
ture for HIV-1 testing with follow-up of results and the lack of
awareness among providers of the potential benefits of early
diagnosis and treatment may also play a role.
Patients presenting to acute care settings were predictably
more symptomatic than those presenting to the health de-
partment. At acute care settings, however, 74% of patients
were seen more than once prior to being diagnosed with AHI,
compared to only one person presenting to the health de-
partment who was seen more than once. These data may be
biased in that patients who presented to the health depart-
ment were typically requesting sexually transmitted disease
(STD) screening in addition to HIV-1 testing. In a subset
analysis of our cohort evaluating missed opportunities for
AHI diagnosis in acute care settings from 1998 to 2001, 10.5%
were diagnosed at time of first visit.23 Some improvement has
been seen with 29.6% being diagnosed in acute care settings at
time of first visit in years 2002–2010. Our results suggest that
these sites need ongoing educational efforts regarding AHI
with better access to diagnostic tools and support recent
measures to facilitate HIV-1 testing in such settings.24
A widely accepted belief is that patients presenting with
AHI invariably have very high viral loads. In this cohort, 10
patients with confirmed AHI (including 8 with negative
EIA tests at diagnosis) never had HIV-1 levels exceeding
10,000 copies/ml. Overall, however, patients had lower initial
CD4 counts and higher HIV-1 levels than other reported
groups.1,22,25,26 Interestingly, the observed range of results
included a substantial proportion with very low CD4 cell
counts during AHI. Eight patients had CD4 counts < 50 cells/
mm3 at time of diagnosis, 6 of whom had negative EIA as-
says. Patients with these levels of HIV-1 RNA and CD4 counts
may have been excluded from other studies based on the
belief that such extremes are not likely among persons with
AHI. Our data illustrate the frequency with which such sub-
stantial variability occurs among individuals with AHI and
represent important observations for providers who may
encounter these patients.
The median time from presentation to diagnosis in our
cohort was only two days, a finding largely attributable to the
substantial proportion of patients diagnosed at publically
funded testing sites in which HIV-1 antibody-negative sam-
ples are screened for AHI in a pooling strategy.15 When con-
sidering only patients presenting initially to acute care
settings, the median time from presentation to diagnosis was
4 days, an improvement from previously published data in
which the median time from presentation to diagnosis was 14
days.23
Despite the short interval from presentation to diagnosis,
the time from estimated infection to presentation was actually
longer for those diagnosed at the health department vs. acute
care sites, perhaps due to the fact that patients at the health
department were less symptomatic with higher CD4 counts
and lower HIV-1 levels. In our analysis we defined estimated
date of infection as 14 days prior to the onset of symptoms,
primarily based on prior work from our own cohort,27 which
is dependent on recall of symptoms. Notably, patients pre-
senting to health departments were younger and more likely
to be African-American. Reasons for these demographic dif-
ferences may be due to limited access to healthcare among
younger persons and African-Americans, resulting in greater
use of publically funded health services.
We observed, as others have, that individuals who were
EIA negative had higher HIV-1 levels than those who were
EIA positive. One common interpretation is that these indi-
viduals are ‘‘earlier’’ in their course of acute infection. How-
ever, we found no significant difference in time from
estimated infection to presentation between patients who
were EIA negative vs. EIA positive. An alternative explana-
tion is that many individuals with AHI captured with a
negative EIA are not diagnosed earlier but instead take longer
to seroconvert due to less robust innate or adaptive immune
responses. Consistent with this hypothesis is our observation
that EIA-negative patients were more apt to be symptomatic
and had lower nadir CD4 counts (5/7 patients with CD4
counts < 50 cells/mm3 were EIA negative). For scientists
studying AHI, preferentially studying subjects who are EIA
negative may result in a bias toward individuals with less
robust immune responses.
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A striking finding is the low number of women enrolled in
our cohort, a trend observed in other AHI studies.22,28 This is
an important observation as women now represent 25% of all
new HIV-1 diagnoses in the United States.29 In the Duke and
UNC HIV Clinics, women constitute one-third of all active
patients. The reasons why women are underrepresented in
this cohort are not entirely clear. Although women < 65 years
old in the United States were more likely than men to have
ever had an HIV test,30 providers may not consider or rec-
ognize HIV infection, including AHI, as frequently in women.
Since women reported fewer symptoms overall than men,
perhaps the diagnosis was less often considered. Women in
our cohort had lower initial HIV-1 levels and higher median
initial CD4 counts than men, a finding also noted by others.22
Increases in the numbers of HIV-1 infections in the South-
eastern United States make the potential for transmission of
HIV-1 during AHI a particular concern. Screening for AHI is
an important target for public health intervention since early
treatment during AHI may alter the immunological de-
cline31,32 and may dramatically reduce the risk of HIV-1
transmission.13 It is notable that 81% of AHI patients in this
cohort elected to be started on antiretroviral therapy within 45
days of diagnosis.33 These data emphasize the increasingly
diverse nature of AHI and provide impetus for improved
approaches to diagnosis going forward.
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